ArriVent BioPharma, Inc.

A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.

AVBP | NDAQ

Overview

Corporate Details

ISIN(s):: US04272N1028
LEI:
Country:: United States of America
Address:: 18 CAMPUS BLVD., NEWTOWN SQUARE
Website:: https://arrivent.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat diseases, with an initial focus on oncology. The company's strategy centers on forging strategic partnerships to in-license and accelerate the global development of promising drug candidates. Its pipeline is led by its lead development candidate, firmonertinib, an investigational cancer therapeutic, and includes other novel oncology treatments such as next-generation antibody-drug conjugates. ArriVent leverages its team's extensive drug development and regulatory expertise to advance its portfolio and address significant unmet medical needs for global patient populations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ArriVent BioPharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ArriVent BioPharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ArriVent BioPharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Genomictree Inc. Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.	South Korea	228760
Genomtec S.A. Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.	Poland	GMT
GENOTECH CORP. A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.	South Korea	066830
Genprex, Inc. A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.	United States of America	GNPX
Gentian Diagnostics ASA Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.	Norway	GENT
GERON CORP Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.	United States of America	GERN
GH Research PLC Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.	United States of America	GHRS
GI Innovation Inc. Develops fusion protein biologics for oncology, allergic, and metabolic diseases.	South Korea	358570
GILEAD SCIENCES, INC. Develops innovative medicines for life-threatening diseases in virology, oncology & inflammation.	United States of America	GILD
GlaxoSmithKline PLC A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.	United Kingdom	GSK